DFTX
Definium Therapeutics, Inc.
Next earnings Jul 29, 2026 · consensus $-0.56 EPS
Last earnings -0.9% on 2026-05-07
$44.95
▲ +0.36%$44.95▲ +537.59%
over 1Y
L $6.49EODHDH $44.95
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.4%
1W+22.6%
1M+91.1%
3M+151.4%
YTD+229.5%
1Y+537.6%
Avoid
Conviction
Horizon
Short (<3mo)
Street · 22 analysts
Strong Buy
Pre-revenue psychedelic biotech burning $132M/yr with binary Phase 3 readouts in mid-to-late 2026 — coin-flip, not an investment.
Definium is a late-stage clinical biopharma with zero revenue across all five reported fiscal years and an accelerating cash burn — FY2025 net loss widened 69.1% to -$184M and operating cash outflow worsened 66.3% to -$132M, driven by an 80.2% jump in R&D to $118M as the company funded three concurrent Phase 3 trials (Voyage, Panorama, Emerge) for DT120 ODT, its lysergide-derived candidate for GAD and MDD. Accumulated deficit has ballooned to -$583M and share count grew 32.3% YoY to 99.7M, confirming the company funds itself by serially diluting shareholders.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$93.9M | -$66.3M | -$93.9M | -$104M | -$166M |
| Net income | -$93.0M | -$56.8M | -$95.7M | -$109M | -$184M |
| Diluted EPS | -$3.40 | -$1.84 | -$2.44 | -$1.54 | -$2.06 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$4.26B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-4.1%
FCF yield—
Quality & risk
ROIC (est.)-35.2%
Free cash flow—
Total debt$40.6M
Net cash$217M
Piotroski F-Score1/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+32.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Material agreement2026-06-24
Material agreement signed (Item 1.01) plus other event disclosure — likely licensing/financing deal.
- 8-K Reg FD disclosure2026-06-22
Reg FD/other-event update; likely pipeline or trial-progress commentary ahead of readouts.
- 8-K Officer / director change2026-06-12
Annual meeting results: director slate elected, exec comp/officer changes ratified.
- 8-K Other event2026-05-19
Other event disclosure — likely conference or pipeline update around Emerge MDD readout.
- 8-K Other event2026-05-12
Other event disclosure following Q1 print; likely investor update or trial timing note.
- 8-K Earnings results2026-05-07
Q1 2026: opex steps up as Voyage/Panorama/Emerge enroll; cash sufficient into key readouts.
- 10-Q Quarterly report2026-05-07
Q1 2026: opex steps up as Voyage/Panorama/Emerge enroll; cash sufficient into key readouts.
- DEF 14A Proxy statement2026-04-27
Proxy filed for 2026 annual meeting — routine director/comp/auditor votes.
- 10-K Annual report2026-02-26
FY25: net loss widened to -$184M, R&D +80% on Phase 3 ramp; cash $258M, debt up.
Recent filings
all on EDGAR ↗4Period ending 2026-06-252026-06-26open ↗4Period ending 2026-06-252026-06-26open ↗4Period ending 2026-06-252026-06-26open ↗4Period ending 2026-06-252026-06-26open ↗4Period ending 2026-06-252026-06-26open ↗144Filing2026-06-25open ↗144Filing2026-06-25open ↗144Filing2026-06-25open ↗144Filing2026-06-25open ↗144Filing2026-06-25open ↗8-KPeriod ending 2026-06-222026-06-24open ↗424B5Filing2026-06-24open ↗
Frequently asked
- Is Definium Therapeutics, Inc. (DFTX) a buy?
- DFTX currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Pre-revenue psychedelic biotech burning $132M/yr with binary Phase 3 readouts in mid-to-late 2026 — coin-flip, not an investment.
- What is Definium Therapeutics, Inc.'s quality score?
- DFTX scores 35.46153846153846/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001813814, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/25/2026, 12:46:16 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.